Ratings for TScan Therapeutics TCRX were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

Morgan Stanley analyst Maxwell Skor assumed coverage of TScan Therapeutics (TCRX) with an Overweight rating and $10 price target Recent Phase ...

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company specializing in T-cell receptor (TCR) therapies with a market capitalization of $102 million, is navigating a critical phase in its ...